Measurements of various aspects of glucose, insulin and lipid metabolism were made before and after the administration of enprostil (a synthetic dehydroprostaglandin E2) for one week to ten patients with non-insulin-dependent diabetes mellitus (NIDDM). Both fasting (P < 0.01) and postprandial (P < 0.001) plasma glucose concentrations were significantly lower after one week of enprostil, and 24 hour urinary glucose excretion was reduced from (mean ± SEM) 47 ± 14 to 25 ± 9 g/day. There was no change in either fasting or postprandial insulin concentration, but the postprandial GIP response was also significantly reduced (P < 0.001). In addition, there were significant reductions in postprandial plasma free fatty acid (P < 0.05) and triglyceride (P < 0.001) concentrations, associated with a modest fall in fasting plasma triglyceride (P < 0.05) and cholesterol (P < 0.07) concentrations when measured after one week of treatment with enprostil. These results raise the possibility that enprostil may be of some benefit in the treatment of patients with non-insulin-dependent diabetes.
|Original language||English (US)|
|Number of pages||4|
|Journal||Hormone and Metabolic Research|
|State||Published - 1988|
ASJC Scopus subject areas